Krystal Biotech (KRYS) EBT (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly EBT of $66.1 million for Q2 2026, up 41.27% year-over-year from $46.8 million in Q2 2025, and up 7.55% on a QoQ basis from $61.4 million in Q1 2026.
Krystal Biotech (KRYS) EBT (2016 - 2026) Analysis & Trends
Krystal Biotech has reported EBT for 11 years, with the latest figure at $66.1 million in Q2 2026.
- EBT for Q2 2026 came in at $66.1 million, up 41.27% year-over-year; the trailing twelve-month figure through Jun 2026 was $226.6 million (up 34.29% YoY), and the FY2025 annual result was $189.5 million, up 98.7% from the prior year.
- EBT advanced to $66.1 million in Q2 2026, from $61.4 million in the prior quarter.
- Over five years, EBT peaked at $80.7 million in Q3 2023 and troughed at -$114.3 million in Q1 2023.
- A 5-year average of $6.4 million and a median of $22.9 million in 2024 frame the typical range for EBT.
- The widest annual swing landed in 2022, when EBT tumbled 106.66%; it then surged 4577.79% in 2025.
- A 5-year view of EBT shows it stood at -$34.0 million in 2022, then surged by 131.32% to $10.7 million in 2023, then surged by 356.13% to $48.6 million in 2024, then advanced by 5.19% to $51.1 million in 2025, then rose by 29.23% to $66.1 million in 2026.
- Per Business Quant data, the three most recent EBT figures were $66.1 million in Q2 2026, $61.4 million in Q1 2026, and $51.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 66.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.08 Mn |
| Mar 31, 2026 | 61.44 Mn |
| Dec 31, 2025 | 51.13 Mn |
| Sep 30, 2025 | 47.97 Mn |
| Jun 30, 2025 | 46.78 Mn |
| Mar 31, 2025 | 43.60 Mn |
| Dec 31, 2024 | 48.61 Mn |
| Sep 30, 2024 | 29.77 Mn |
| Jun 30, 2024 | 16.05 Mn |
| Mar 31, 2024 | 932,000.00 |
| Dec 31, 2023 | 10.66 Mn |
| Sep 30, 2023 | 80.75 Mn |
| Jun 30, 2023 | -33.21 Mn |
| Mar 31, 2023 | -114.32 Mn |
| Dec 31, 2022 | -34.02 Mn |
| Sep 30, 2022 | -68.59 Mn |
| Jun 30, 2022 | -57.44 Mn |
| Mar 31, 2022 | -81.62 Mn |
| Dec 31, 2021 | -22.03 Mn |
| Sep 30, 2021 | -25.10 Mn |